Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma

Survival of patients with relapsed/refractory osteosarcoma has not improved in the last 30 years. Several immunotherapeutic approaches have shown benefit in murine osteosarcoma models, including the anti‐programmed death‐1 (anti‐PD‐1) and anti‐cytotoxic T‐lymphocyte antigen‐4 (anti‐CTLA‐4) immune ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Hennessy, Marlene, Wahba, Andrew, Felix, Kumar, Cabrera, Mariella, Segura, Maria Gabriela, Kundra, Vikas, Ravoori, Murali K., Stewart, John, Kleinerman, Eugenie S., Jensen, Vanessa Behrana, Gopalakrishnan, Vidya, Pena, Rhoneil, Quach, Phi, Kim, Grace, Kivimäe, Saul, Madakamutil, Loui, Overwijk, Willem W., Zalevsky, Jonathan, Gordon, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984260/
https://www.ncbi.nlm.nih.gov/pubmed/33152115
http://dx.doi.org/10.1002/ijc.33382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984260/
https://www.ncbi.nlm.nih.gov/pubmed/33152115
http://dx.doi.org/10.1002/ijc.33382

Ejemplares similares